Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

Explore how immune time-resolved Förster resonance energy transfer (iFRET) offers new insights into predicting immunotherapy ...

New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...

The C-POST trial marks the first immunotherapy to show a clear ... have not demonstrated success in the adjuvant treatment of high-risk CSCC. 2 Cemiplimab’s promising results highlight the ...

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...